Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D05IHU
|
||||
| Former ID |
DIB002792
|
||||
| Drug Name |
Tetrahydrozoline
|
||||
| Synonyms |
Tyzine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Ocular disease [ICD10:H00-H59] | Approved | [1] | ||
| Company |
Fougera Pharmaceuticals Inc
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C13H17ClN2
|
||||
| Canonical SMILES |
C1(c2c(CCC1)cccc2)C1=NCCN1
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Alpha-2C adrenergic receptor | Target Info | Modulator | [1], [2] | |
| KEGG Pathway | cGMP-PKG signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| PANTHER Pathway | Alpha adrenergic receptor signaling pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| Reactome | Adrenoceptors | ||||
| Adrenaline signalling through Alpha-2 adrenergic receptor | |||||
| Adrenaline,noradrenaline inhibits insulin secretion | |||||
| G alpha (i) signalling events | |||||
| G alpha (z) signalling events | |||||
| Surfactant metabolism | |||||
| WikiPathways | Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| Platelet Aggregation (Plug Formation) | |||||
| Integration of energy metabolism | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Prolonged cardiovascular effects after unintentional ingestion of tetrahydrozoline. Clin Toxicol (Phila). 2008 Feb;46(2):171-2. | ||||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.